U.S. Tissue Engineering Market (By Application: Cord Blood & Cell Banking, Cancer, Dental, Skin & Integumentary, Urology, Neurology) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The U.S. tissue engineering market size was estimated at around USD 8.12 billion in 2023 and it is projected to hit around USD 28.66 billion by 2033, growing at a CAGR of 13.44% from 2024 to 2033.

Key Pointers

• By Application, the orthopedics, musculoskeletal, and spine sectors generated the maximum market share of 60% in 2023.
• By Application, the cardiology and vascular sector is anticipated to grow at the noteworthy CAGR of 25.02% from 2024 to 2033.

U.S. Tissue Engineering Market Overview

Tissue engineering stands at the forefront of medical innovation, offering promising solutions for a wide array of healthcare challenges. In the United States, the tissue engineering market is experiencing significant growth, driven by advancements in regenerative medicine, increasing research and development activities, and a growing demand for personalized healthcare solutions. This overview delves into the key factors shaping the U.S. tissue engineering market landscape.

U.S. Tissue Engineering Market Growth Factors

The growth of the U.S. tissue engineering market is driven by an advancements in biotechnology and regenerative medicine have led to the development of innovative tissue engineering techniques, such as 3D bioprinting and scaffold-based approaches, driving market expansion. Secondly, the rising incidence of chronic diseases, coupled with an aging population, has created a growing demand for tissue-engineered products and therapies to address unmet medical needs. Additionally, significant investments in research and development, both from public and private sectors, fuel continuous innovation and drive market growth. Furthermore, a supportive regulatory landscape, overseen by the Food and Drug Administration (FDA), ensures safety and efficacy standards are met, facilitating market access for tissue-engineered products.

U.S. Tissue Engineering Market Trends:

• Advancements in Biotechnology: The U.S. tissue engineering market is witnessing rapid advancements in biotechnology, particularly in areas such as stem cell research, gene editing technologies, and biomaterials. These innovations are driving the development of novel tissue engineering techniques and products, enhancing the scope and efficacy of regenerative therapies.
• Growing Demand for Personalized Healthcare Solutions: With an increasing emphasis on personalized medicine, there is a growing demand for tissue-engineered products tailored to individual patient needs. Advancements in tissue engineering technologies, such as patient-specific 3D bioprinting and organ-on-a-chip models, are enabling the customization of therapies, leading to better treatment outcomes and patient satisfaction.
• Integration of Artificial Intelligence and Machine Learning: Artificial intelligence (AI) and machine learning (ML) are increasingly being integrated into tissue engineering research and development processes. These technologies facilitate data analysis, predictive modeling, and optimization of tissue engineering protocols, accelerating the discovery of novel biomaterials, and enhancing tissue regeneration outcomes.
• Expansion of 3D Bioprinting Applications: 3D bioprinting technology continues to evolve, expanding its applications across various tissue engineering fields. From the fabrication of complex tissue constructs to the creation of patient-specific implants and organoids, 3D bioprinting offers unprecedented precision and versatility, driving innovation in tissue engineering research and clinical practice.
• Emphasis on Regenerative Medicine: Regenerative medicine approaches, including tissue engineering, hold immense promise for treating a wide range of medical conditions, including orthopedic injuries, cardiovascular diseases, and skin disorders. The U.S. tissue engineering market is witnessing a shift towards regenerative therapies that promote tissue repair and regeneration, offering new avenues for disease management and improved patient outcomes.

Application Insights

The orthopedics, musculoskeletal, and spine sectors dominated the market in 2023, holding the largest revenue share of 60%. The increase in musculoskeletal disorders has fueled the adoption of tissue engineering as a crucial treatment method for orthopedic surgeons. This approach effectively addresses various disorders, ranging from meniscal deficits in young athletes to osteochondral abnormalities in the glenohumeral joint. The market is poised for further growth due to the implementation of diverse growth strategies by market players and the introduction of new products. For example, in October 2022, LifeNet Health presented its advanced allograft biologics for fusion at the North American Spine Society (NASS) 2022 Annual Meeting in Chicago. This included ViviGen MIS, the first viable cellular allograft delivery device designed for minimally invasive surgery.

The cardiology and vascular sector are projected to witness the fastest compound annual growth rate (CAGR) of 25.02% during the forecast period. The rapid growth of this segment is driven by the pressing need for innovative solutions in cardiac care. Tissue engineering holds promise in creating cardiac grafts and regenerating tissues without eliciting adverse effects such as immunogenicity. The utilization of advanced biomaterials, such as synthetic polymers like polyglycolic acid and polylactic acid, in cardiac tissue engineering has significantly contributed to this growth. These advancements facilitate the development of functional and viable engineered tissues, addressing challenges in cardiac care and propelling the swift expansion of tissue-engineered products in cardiology.

U.S. Tissue Engineering Market Key Companies

• Zimmer Biomet Holdings, Inc.
• AbbVie (Allergan)
• Becton Dickinson and Company
• B. Braun
• Integra LifeSciences Corporation
• Organogenesis Holdings Inc.
• Medtronic
• ACell, Inc.
• Athersys, Inc.
• Tissue Regenix Group plc
• Stryker Corporation
• RTI Surgical, Inc.
• ReproCell, Inc.
• Baxter International, Inc.

Recent Developments

• In August 2023, AbbVie completed a merger with Allergan in Japan following a global acquisition. This strategic merger aimed to capitalize on Allergan's expertise and resources, thereby strengthening AbbVie's position in the field of regenerative medicine and tissue engineering solutions. The goal was to drive innovation and foster market growth within these sectors.
• In June 2023, BD inaugurated a new research and development facility in Blackrock, Dublin. Additionally, it announced plans for further investment to expand its manufacturing facility in Enniscorthy, Wexford. These strategic initiatives are intended to bolster BD's presence in Ireland's burgeoning tissue engineering industry. By leveraging Ireland's supportive environment for research and development, BD aims to stimulate innovation and fuel growth within this sector.

U.S. Tissue Engineering Market Segmentations:

By Application

• Cord Blood & Cell Banking
• Cancer
• GI, Gynecology
• Dental
• Skin & Integumentary
• Urology
• Orthopedics, Musculoskeletal, & Spine
• Neurology
• Cardiology & Vascular
• Others